The main points of the forthcoming recommendations were described at the French-speaking Days of Hepato-Gastroenterology and ...

About half of patients with severe asthma have elevated circulating levels of eosinophils, a type of white blood cell.

The "Eosinophilic Esophagitis - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.Eosinophilic Esophagitis (EoE) is increasingly recognized as a chronic disorder ...

In a slow week, the FDA has approved Fasenra for children 6 to 11 years of age with eosinophilic asthma, a rare form of ...

Endoscopy and biopsies can confirm a diagnosis (Attwood explains there are disease marker white blood cells, called eosinophils, which stain pink under the microscope). Treatment can include steroid ...

The maintenance treatment for severe asthma with an eosinophilic phenotype originally was approved for patients aged 12 years ...

Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300 ...

Recent research links short-term heat exposure to increased inflammation and weakened immunity, particularly affecting ...

The FDA on Thursday approved the label expansion of AstraZeneca’s Fasenra as an add-on maintenance treatment for severe ...

General Meeting ofCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual General Meeting is attached.

FASENRA is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of blood and tissue eosinophils ...

The Board of Directors of Care ASA ("HBC") has approved the financial statements for 2023 and the Company has today published the Annual Report and Sustainability Report for 2023. Please find the ...